From Copycats to Global Champions: The Remarkable Journey of Indian Pharma

By Jaya Prakash Pradhan December 5, 2006 939

Print Article

Type	Working paper
Title	“Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies”
Author	Jaya Prakash Pradhan
Published	2006 · ISID Working Paper No. WP2006/05 · Institute for Studies in Industrial Development, New Delhi
Coverage	Indian pharmaceutical industry · 1950s–2006
Read	Working paper (PDF)

This is a plain-language summary of “Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies” (Pradhan, ISID Working Paper No. WP2006/05, 2006).

In short:

Over five decades, strategic government policy turned India from an import-dependent country into a fast-growing, cost-effective producer of quality drugs with consistent trade surpluses.
But the paper is careful to balance that success with real limitations: productivity and R&D intensity lagged global peers, and India held only a small share — around 1% — of global pharma export value.
The honest read is that India became a volume and cost leader, not yet an innovation and value leader — and the paper sets out the strategies firms were using to close that gap.

The transformation — and the caveat

India’s pharmaceutical story is genuinely striking: from barely being able to manufacture basic drugs in the 1950s to becoming a major supplier of affordable generic medicines worldwide. This widely-cited working paper by Jaya Prakash Pradhan tells that story — but its real contribution is to pair the triumph with a clear-eyed assessment of where India still fell short on competitiveness. It’s both a celebration and a diagnosis.

How it happened: four stages

The paper frames the industry’s rise as a four-stage evolution, driven throughout by deliberate policy.

In the foundation years (1950s–60s), India depended heavily on foreign companies, and the government seeded the sector with public-sector firms like IDPL and Hindustan Antibiotics. The decisive turn came with the 1970 Patent Act, which — by recognising process but not product patents — let Indian firms develop their own methods to make existing drugs, producing quality medicines far more cheaply. The 1980s brought self-reliance, as firms moved from basic drugs to complex formulations and began exporting to other developing countries. And from the 1990s, the industry made its “global leap,” competing internationally and expanding through acquisitions and overseas operations. The throughline the paper emphasises is that strategic government policy — the patent regime above all — was the main engine of this transformation.

Strengths and limits — the heart of the paper

Where the live story tends to celebrate, the paper insists on balance, and this is its most useful contribution.

On the strengths side, India had become one of the fastest-growing pharmaceutical industries in the world: a cost-effective producer of quality drugs, running consistent trade surpluses, with world-class manufacturing capacity and a large share of its own domestic drug needs met at home. But the paper is equally clear about the limits. India’s productivity lagged global competitors; its R&D intensity remained relatively low, a serious vulnerability in an industry where original innovation increasingly drives value; and despite the impressive volumes, India accounted for only around 1% of global pharmaceutical export value. The distinction the paper draws is the important one: India had become a formidable cost and volume competitor, but not yet a leader in innovation and high-value pharmaceuticals — and bridging that gap was the central challenge ahead.

How firms were responding

The paper catalogues the competitive strategies Indian pharma firms were adopting to move up that value ladder: overseas acquisitions (Ranbaxy, Dr Reddy’s and others buying foreign firms for market and technology access), strategic alliances and contract manufacturing (producing for global firms and partnering on research and marketing), and greenfield direct investment (own subsidiaries and distribution networks abroad). These were the practical means by which Indian firms sought new markets, technologies, and a foothold higher up the value chain.

What it recommends

The paper’s policy prescriptions follow directly from the diagnosis: encourage consolidation among domestic firms to build the scale that global competition demands; boost R&D spending to address the innovation gap; support overseas acquisitions as a route to markets and technology; and provide incentives for innovation. The underlying message is that India’s pharma success was real but unfinished — built on cost-competitive manufacturing, and needing a deliberate push on productivity and research to become a genuine innovation leader rather than primarily a low-cost producer.

Read the academic abstract

What are the trends in the global competitiveness of the Indian pharmaceutical industry? Where does it stand against global peers on pharmaceutical value-added, productivity, R&D, and trade performance? And what new strategies are Indian pharmaceutical companies adopting to become global players? This paper addresses these questions. It finds that strategic government policies were the main factors that transformed the Indian pharmaceutical industry from a mere importer and distributor of drugs into an innovation-driven, cost-effective producer of quality medicines. India emerged as one of the fastest-growing pharmaceutical industries in the world, with growing trade surpluses and exports. However, certain limitations remain for policy to address — notably low productivity and low R&D intensity. A range of competitive strategies — greenfield direct investment, overseas acquisitions, strategic alliances, and contract manufacturing — have recently become favoured approaches among Indian pharmaceutical firms.

Cite this working paper

Pradhan, J. P. (2006). Global competitiveness of Indian pharmaceutical industry: Trends and strategies (ISID Working Paper No. WP2006/05). New Delhi: Institute for Studies in Industrial Development.

Read the working paper (PDF) →